Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024

Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India

Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI

Bristol Myers Squibb inaugurates new US$100 million facility in Hyderabad

The facility will accommodate over 1,500 employees

AstraZeneca completes acquisition of Gracell

The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F

AstraZeneca completes acquisition of Icosavax

The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus

GSK completes acquisition of Aiolos Bio

The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody

YS Biopharma appoints new Directors

The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024

Ascentage Pharma’s Phase III study of Olverembatinib cleared by FDA

The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.